Compare Ascendis Pharma A/S (ASND) vs Global X Cloud Computing ETF (CLOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Global X Cloud Computing ETF — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Global X Cloud Computing ETF trades at $24.22. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Global X Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| ASND | CLOU | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $26.38 |
52-Week Low | $163.32 | $17.60 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CLOU trades at $23.76, down 1.47% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF tracks cloud computing stocks, though key financial ratios are unavailable. Recent news highlights mixed sentiment, with some outlets pointing to underperformance while others discuss AI-driven growth potential in the sector.
Outlook hinges on cloud computing adoption and AI integration, offering growth exposure but with volatility risks from tech sector swings and competitive pressures. Investors should weigh the sector's long-term trends against near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →
